Q-omics provides the consensus-scored MARF1 profile across patient tissues and cancer cell-line models. MARF1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MARF1 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, MARF1 RNA expression shows 21,587 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where MARF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MARF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MARF1 survival associations across molecular data types. MARF1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MARF1 RNA expression–survival associations across cancer types. High MARF1 expression shows unfavorable associations in ACC and ESCA, but favorable associations in KIRC, HNSC, LGG and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MARF1 RNA expression.
This table summarizes MARF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MARF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MARF1 shows lower tumor expression in THCA, UCEC, KICH and COAD and higher tumor expression in HNSC and LIHC. The THCA box plot shows higher MARF1 RNA expression in normal versus tumor tissue (log2 FC = −0.570, t-test p < 0.001).
This table shows molecular features associated with MARF1 in patient tissues and cancer cell lines. In patient samples, MARF1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MARF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
